 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
How Will OIG's Findings on Widely Divergent Gene Test Reimbursement Rates Influence CMS Payment?
June 20, 2012
How Will OIG's Findings on Widely Divergent Gene Test Reimbursement Rates Influence CMS Payment?
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Ahead of FDA Meeting on LDTs, Test Developers Prep for Increased Oversight, but Greater Clarity
July 7, 2010 / Pharmacogenomics Reporter - CMS Stance on Reimbursement of Multi-Analyte Algorithm Assays Raises Industry Concerns
September 19, 2012 / Pharmacogenomics Reporter - NanoString on Track to Launch Breast Cancer Subtyping Test in EU with CE Mark, in US with FDA OK
August 15, 2012 / Pharmacogenomics Reporter - Deal with NewBridge Allows Genomic Health to Expand Oncotype DX into Africa, Middle East
August 13, 2012 / GenomeWeb Daily News - Prospective Comparison of Oncotype DX and Central Pathology Assessment Shows HER2 Discordance
July 3, 2012 / Pharmacogenomics Reporter